ST
LGND icon

Spot Trading’s Ligand Pharmaceuticals LGND Stock Holding History

Spot Trading’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,348
Closed -$719K – 3153
2016
Q4 		$719K Buy
+11,348
New +$716K 0.02% 1180
2015
Q1 		– Sell
-3,240
Closed -$108K – 4121
2014
Q4 		$108K Buy
+3,240
New +$105K ﹤0.01% 3205

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Spot Trading's LGND Position: Q1 2017 in Review

Spot Trading sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 11,348 shares — an estimated $719K sold.

Spot Trading first reported a position in LGND in Q4 2014 and held it in 2 quarters. The position peaked at $719K in Q4 2016. 256 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

  • Spot Trading reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Spot Trading sold 11,348 Ligand Pharmaceuticals shares in Q1 2017, an estimated $719K.
  • Spot Trading first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Spot Trading's Ligand Pharmaceuticals position peaked at $719K in Q4 2016.
  • 256 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Spot Trading's 13F filing for Q1 2017, filed 1 May 2017.